Table III.

MLTC-derived CD8+ T cells lyse AuTu-AWE-DC or whole autologous tumor targets but not autologous DC pulsed with AWE from allogeneic tumors or whole allogeneic tumor targets

CTL Donorsa (patient no.)AWEb /Whole Tumor Cellc Donors (Patient No.)
12345678910
140b /45c,d3/21 /22/5 27 /22 2/32/31 /2 20 /23 1 /4
21 /2 17/20 3 /10.5/12 /21/10.5/11 /12 /31 /2
33 /25/4 25 /21 3/25 /36/54/23 /32 /15 /3
41 /32/53 /3 34/35 3 /25/33/55 /23 /33 /6
5 20 /17 3/51 /31/2 35 /39 2/11/12 /3 25 /20 3 /3
62 /53/42 /12/23 /3 26/23 4/21 /35 /23 /5
71 /10.5/12 /23/42 /35/2 32/30 3 /24 /35 /2
83 /25/41 /10.5/22 /22/35/2 37 /42 1 /12 /2
9 19 /17 3/65 /33/4 17 /20 0.5/11/26 /5 29 /32 2 /3
105 /23/36/53/27/53/52/33/32 /5 22 /25
  • a MLTC-activated CD8+ CTL were tested in cytotoxicity assays against autologous DCs pulsed with AWE from autologous or allogeneic tumors or against whole autologous or allogeneic tumor targets. Results are expressed as mean percent cytotoxicity from triplicate cultures. The SD never exceeded 25% of the means and thus is omitted.

  • b Autologous or allogeneic tumors.

  • c Whole autologous or allogeneic tumor targets.

  • d Values in bold indicate statistically significant (p < 0.01) lytic responses over background values.